18F-Labelled Inorganic Fluorides & Radiopharmaceuticals
our initial collaborations with Prof.
E. S. Garnett and Prof. R. V. Chirakal (McMaster Nuclear Medicine) in 1981,
the expertise and techniques developed
in our fundamental fluorine chemistry programs have been transferred to the
field of Nuclear Medicine and to the syntheses of [18F]-radiopharmaceuticals
(18F; a positron-emitting isotope of high specific activity and
short half-life, 110 min, that is prepared using the Nuclear Medicine's cyclotron).
Both [18F]F2, and [18F]XeF2 have
been utilized for electrophilic radiofluorinations of a variety of compounds
of biological interest, and in particular those which are of use for in vivo
imaging of the human brain, e.g., [18F]fluorodopamine, [18F]fluoro-5-hydroxy-tryptophan,
[18F]6-fluoro-3,4-dihydroxy-phenyl serine and [18F]2-deoxy-2-fluoro-glucose).
These and other [18F]-labelled radiopharmaceuticals developed in
collaboration with Prof. Chirakal's team to investigate, non-invasively, cerebral
metabolism and disorders of the human brain such as Parkinson's disease and
schizophrenia by positron emission tomography (P.E.T.). Recently, a reliable
procedure for the formation of the 18F-labelled rare sugar, allose,
was developed and shown, in an animal study, to have potential for breast
tumor imaging and the assessment of lung fibrosis. Another recent discovery
that melanoma tumors in mice can be imaged using an 18F-radiotracer
is equally exciting.